The BD Soluvia microinjection system offers a reliable method of intradermal delivery, which integrates a 1.5mm length BD microneedle with a 0.1ml injected volume. As a prefillable delivery device, the BD Soluvia microinjection system also provides key safety benefits for patients and the healthcare system, such as a high level of sterility assurance and reduced risks associated with vaccine preparation and administration, the company said.
The approval of the first ID microinjection influenza vaccine follows the favorable evaluation from the European Medicines Agency in December 2008 based on the review of data from clinical trials conducted by Sanofi Pasteur.
Philippe Laurent, vice president of medical affairs for medical and pharmaceutical systems at BD, said: “BD is pleased to have its innovative microinjection system be part of the first intradermal flu vaccine. The minimally invasive BD Soluvia microinjection system has the potential to increase patient participation in immunization programs.”